

Merel van Nuland

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8025540/publications.pdf>

Version: 2024-02-01

15
papers

215
citations

932766
10
h-index

1058022
14
g-index

15
all docs

15
docs citations

15
times ranked

298
citing authors

#	ARTICLE	IF	CITATIONS
1	Therapeutic Drug Monitoring of Oral Anti-Hormonal Drugs in Oncology. <i>Clinical Pharmacokinetics</i> , 2019, 58, 299-308.	1.6	41
2	Development and Validation of an LC-MS/MS Method for the Simultaneous Quantification of Abiraterone, Enzalutamide, and Their Major Metabolites in Human Plasma. <i>Therapeutic Drug Monitoring</i> , 2017, 39, 243-251.	1.0	28
3	Development and validation of an UPLC-MS/MS method for the therapeutic drug monitoring of oral anti-hormonal drugs in oncology. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2019, 1106-1107, 26-34.	1.2	22
4	Exposure-response analyses of abiraterone and its metabolites in real-world patients with metastatic castration-resistant prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 244-251.	2.0	19
5	Predictive Value of Microdose Pharmacokinetics. <i>Clinical Pharmacokinetics</i> , 2019, 58, 1221-1236.	1.6	16
6	LC-MS/MS assay for the quantification of testosterone, dihydrotestosterone, androstenedione, cortisol and prednisone in plasma from castrated prostate cancer patients treated with abiraterone acetate or enzalutamide. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2019, 170, 161-168.	1.4	16
7	Ultra-sensitive LC-MS/MS method for the quantification of gemcitabine and its metabolite 2,2-difluorodeoxyuridine in human plasma for a microdose clinical trial. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2018, 151, 25-31.	1.4	15
8	Bioanalytical LC-MS/MS validation of therapeutic drug monitoring assays in oncology. <i>Biomedical Chromatography</i> , 2020, 34, e4623.	0.8	13
9	Cost-effectiveness of monitoring endoxifen levels in breast cancer patients adjuvantly treated with tamoxifen. <i>Breast Cancer Research and Treatment</i> , 2018, 172, 143-150.	1.1	12
10	An LC-MS/MS method for quantification of the active abiraterone metabolite \hat{I}^* (4)-abiraterone (D4A) in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2017, 1068-1069, 119-124.	1.2	11
11	Exposure-Response Assessment of Enzalutamide and Its Major Metabolites in a Real-World Cohort of Patients with Metastatic Castration-Resistant Prostate Cancer. <i>Pharmacotherapy</i> , 2019, 39, 1137-1145.	1.2	9
12	Plasma Levels of Enzalutamide and Its Main Metabolites in a Patient With Metastatic Castration-resistant Prostate Cancer Undergoing Hemodialysis. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e383-e386.	0.9	7
13	Dosing Therapeutic Radiopharmaceuticals in Obese Patients. <i>International Journal of Molecular Sciences</i> , 2022, 23, 818.	1.8	4
14	Pilot Study to Predict Pharmacokinetics of a Therapeutic Gemcitabine Dose From a Microdose. <i>Clinical Pharmacology in Drug Development</i> , 2020, 9, 929-937.	0.8	2
15	Efficacy, Tolerance, and Plasma Levels of Abiraterone and Its Main Metabolites in a Patient With Metastatic Castration-resistant Prostate Cancer With a Hepatic Transplant. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e893-e896.	0.9	0